A detailed history of Meridian Investment Counsel Inc. transactions in Gilead Sciences, Inc. stock. As of the latest transaction made, Meridian Investment Counsel Inc. holds 23,672 shares of GILD stock, worth $2.1 Million. This represents 0.52% of its overall portfolio holdings.

Number of Shares
23,672
Previous 23,862 0.8%
Holding current value
$2.1 Million
Previous $1.75 Million 7.04%
% of portfolio
0.52%
Previous 0.59%

Shares

27 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Jul 19, 2024

SELL
$63.15 - $72.88 $11,998 - $13,847
-190 Reduced 0.8%
23,672 $1.62 Million
Q1 2024

May 13, 2024

SELL
$71.58 - $87.29 $14,101 - $17,196
-197 Reduced 0.82%
23,862 $1.75 Million
Q4 2023

Feb 09, 2024

SELL
$73.27 - $83.09 $25,644 - $29,081
-350 Reduced 1.43%
24,059 $1.95 Million
Q3 2023

Nov 03, 2023

SELL
$73.94 - $80.67 $59,152 - $64,536
-800 Reduced 3.17%
24,409 $1.83 Million
Q1 2023

May 05, 2023

SELL
$77.31 - $88.08 $15,462 - $17,616
-200 Reduced 0.79%
25,209 $2.09 Million
Q4 2022

Feb 06, 2023

SELL
$62.32 - $89.47 $38,950 - $55,918
-625 Reduced 2.4%
25,409 $2.18 Million
Q3 2022

Nov 08, 2022

SELL
$59.54 - $68.01 $7,442 - $8,501
-125 Reduced 0.48%
26,034 $1.61 Million
Q2 2022

Aug 11, 2022

SELL
$57.72 - $65.01 $65,916 - $74,241
-1,142 Reduced 4.18%
26,159 $1.62 Million
Q4 2021

Feb 14, 2022

SELL
$64.88 - $73.64 $17,842 - $20,251
-275 Reduced 1.0%
27,301 $1.98 Million
Q3 2021

Oct 27, 2021

SELL
$67.69 - $73.03 $37,229 - $40,166
-550 Reduced 1.96%
27,576 $1.93 Million
Q2 2021

Jul 23, 2021

BUY
$63.47 - $69.35 $6,029 - $6,588
95 Added 0.34%
28,126 $1.94 Million
Q1 2021

May 03, 2021

SELL
$60.0 - $68.46 $6,000 - $6,845
-100 Reduced 0.36%
28,031 $1.81 Million
Q4 2020

Feb 03, 2021

SELL
$56.65 - $64.55 $31,157 - $35,502
-550 Reduced 1.92%
28,131 $1.64 Million
Q3 2020

Oct 23, 2020

SELL
$62.1 - $78.08 $6,210 - $7,808
-100 Reduced 0.35%
28,681 $1.81 Million
Q2 2020

Aug 05, 2020

BUY
$72.34 - $84.0 $14,829 - $17,220
205 Added 0.72%
28,781 $2.21 Million
Q1 2020

Apr 30, 2020

SELL
$62.63 - $80.22 $43,841 - $56,154
-700 Reduced 2.39%
28,576 $2.14 Million
Q4 2019

Feb 06, 2020

SELL
$61.62 - $67.78 $18,486 - $20,334
-300 Reduced 1.01%
29,276 $1.9 Million
Q3 2019

Oct 25, 2019

SELL
$62.51 - $69.0 $9,376 - $10,350
-150 Reduced 0.5%
29,576 $1.88 Million
Q2 2019

Aug 13, 2019

SELL
$61.87 - $69.38 $680 - $763
-11 Reduced 0.04%
29,726 $2.01 Million
Q1 2019

May 06, 2019

SELL
$62.53 - $70.05 $43,771 - $49,035
-700 Reduced 2.3%
29,737 $1.93 Million
Q4 2018

Feb 13, 2019

SELL
$60.54 - $79.0 $18,162 - $23,700
-300 Reduced 0.98%
30,437 $1.9 Million
Q3 2018

Nov 05, 2018

SELL
$71.28 - $78.92 $8,553 - $9,470
-120 Reduced 0.39%
30,737 $2.37 Million
Q2 2018

Aug 08, 2018

BUY
$64.88 - $75.68 $3,244 - $3,784
50 Added 0.16%
30,857 $2.19 Million
Q1 2018

May 14, 2018

BUY
$72.84 - $88.8 $222,162 - $270,840
3,050 Added 10.99%
30,807 $2.32 Million
Q4 2017

Feb 13, 2018

BUY
$71.15 - $83.52 $363,576 - $426,787
5,110 Added 22.56%
27,757 $1.99 Million
Q3 2017

Nov 08, 2017

BUY
$72.11 - $85.47 $57,688 - $68,376
800 Added 3.66%
22,647 $1.84 Million
Q2 2017

Aug 14, 2017

BUY
N/A
21,847
21,847 $1.55 Million

Others Institutions Holding GILD

About GILEAD SCIENCES, INC.


  • Ticker GILD
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 1,253,369,984
  • Market Cap $111B
  • Description
  • Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, a...
More about GILD
Track This Portfolio

Track Meridian Investment Counsel Inc. Portfolio

Follow Meridian Investment Counsel Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Meridian Investment Counsel Inc., based on Form 13F filings with the SEC.

News

Stay updated on Meridian Investment Counsel Inc. with notifications on news.